DxTerity Earns SOC 2 Type 2 Compliance, Reinforcing Commitment to Secure Healthcare Data. Read more
  {modal url="index.php?option=com_content&view=category&layout=blog&id=18&Itemid=125" class="modalsign"}{/modal}

Banner

Blog

Better insight into your Lupus care

{source}<!--[if lte IE 8]>
<script charset="utf-8" type="text/javascript" src="//js.hsforms.net/forms/v2-legacy.js"></script>
<![endif]-->
<script charset="utf-8" type="text/javascript" src="//js.hsforms.net/forms/v2.js"></script>
<script>
hbspt.forms.create({
region: "na1",
portalId: "6638220",
formId: "2c8cc060-7da6-4af3-8bf7-3061139a40e4",
onFormSubmit: function($data) {
var pdf = "https://dxterity.com/images/pdf/home_resources/20220422_IFN-1_White_Paper.pdf";
window.open(pdf);
}
});
</script>
{/source}

White Paper

Two new lupus therapies target the influential IFN-1 pathway

To learn more about IFN-1 targeted therapies, download our white paper
img white paper 2 thumbnail

Better health management begins
at home

Subscribe to receive the latest information on new developments and products at DxTerity.